Deallus thought leadership

The latest from Deallus pharmaceutical and life science industry experts

Remdesivir’s journey and its impact on share price

2020-09-04T11:37:04+01:00News, Thought Piece|

The COVID-19 pandemic will shape several future market trends within the pharmaceutical industry. In terms of emerging macro trends, one notable impact of COVID-19 has been on the stock market within the healthcare sector, historically considered a safe haven for investors during financial crises. Our infographic plots significant events in Remdesivir’s recent history to contextualize this dramatic story and the seemingly disproportionate impact one product’s journey appeared to have on the overall company stock price.

OnDemand Webinar – Navigating Market Disruption after COVID-19

2020-09-04T10:32:33+01:00News, Thought Piece, Video|

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussions on ‘Navigating Market Disruption After Covid-19’. This OnDemand webinar discusses how the pandemic has accelerated market shifts already in play, disrupting current business models, and dramatically altering how pharma business will be done in the future.

COVID-19 – tracking the fast-moving landscape

2020-09-04T11:07:24+01:00Thought Piece|

As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.

COVID-19, China, and Telemedicine

2020-09-04T11:12:46+01:00Thought Piece|

As COVID-19 continues to disrupt normalcy across the globe, China is responding with innovation in online health delivery and telemedicine. How has China encouraged telemedicine uptake? What are the factors contributing to China’s relatively quick utilization of telemedicine in the face of COVID-19? And what learnings can we gain from taking a closer look? We explore these questions in our latest addition to our COVID-19+Pharma Series.

Launch and COVID-19: Pharma’s Dilemma

2020-09-04T11:00:11+01:00Thought Piece|

COVID-19 is throwing a wrench in years’ worth of launch planning, introducing complications and delays into the regulatory process and severely constricting promotional and educational opportunities for new products. How is the pharmaceutical industry responding to these changes in well-laid plans? How are regulatory bodies responding? We consider the potential impact of the pandemic on launch timing and strategy here.

How is COVID-19 impacting clinical trials?

2020-05-14T15:20:58+01:00Thought Piece|

As the impact of COVID-19 pandemic continues to expand globally, pharmaceutical and biotech players are beginning to feel the disruptive effects of the outbreak. New clinical trials will be significantly delayed as companies continue to face challenges arising from COVID-19, from potential patient quarantines, to site closures, travel limitations or interruptions to the supply chain for new investigational products.

Go to Top